American Association for Cancer Research
00085472can123929-sup-can-12-3929fig1-4.pdf (410.36 kB)

Supplementary Figures 1 - 4 from The Steroid Receptor Coactivator-3 Is Required for the Development of Castration-Resistant Prostate Cancer

Download (410.36 kB)
journal contribution
posted on 2023-03-30, 21:55 authored by Jean C-Y. Tien, Zhaoliang Liu, Lan Liao, Fen Wang, Yixiang Xu, Ye-Lin Wu, Niya Zhou, Michael Ittmann, Jianming Xu

PDF file - 410K, Supplementary Figure S1. SRC-3 knockout in prostate epithelial cells does not affect prostate morphogenesis during development. Supplementary Figure S2. Deletion of SRC-3 has no impact on tumor histology or cellular proliferation in non-castrated 12-week-old mice. Supplementary Figure S3. Immunohistochemistry for pRPS6 in prostate tumors of castrated PtenCKO and Pten3CKO mice. Supplementary Figure S4. SRC-3 deletion does not change AR protein level in tissue lysate and AR target genes.



The transcriptional coactivator SRC-3 plays a key role in enhancing prostate cancer cell proliferation. Although SRC-3 is highly expressed in advanced prostate cancer, its role in castration-resistant prostate cancer (CRPC) driven by PTEN mutation is unknown. We documented elevated SRC-3 in human CRPC and in PTEN-negative human prostate cancer. Patients with high SRC-3 and undetectable PTEN exhibited decreased recurrence-free survival. To explore the causal relationship in these observations, we generated mice in which both Pten and SRC-3 were inactivated in prostate epithelial cells (Pten3CKO mice), comparing them with mice in which only Pten was inactivated in these cells (PtenCKO mice). SRC-3 deletion impaired cellular proliferation and reduced tumor size. Notably, while castration of PtenCKO control mice increased the aggressiveness of prostate tumors relative to noncastrated counterparts, deletion of SRC-3 in Pten3CKO mice reversed all these changes. In support of this finding, castrated Pten3CKO mice also exhibited decreased levels of phospho-Akt, S6 kinase (RPS6KB1), and phosphorylated S6 protein (RPS6), all of which mediate cell growth and proliferation. Moreover, these tumors appeared to be more differentiated as evidenced by higher levels of Fkbp5, an AR-responsive gene that inhibits Akt signaling. Lastly, these tumors also displayed lower levels of certain androgen-repressed genes such as cyclin E2 and MMP10. Together, our results show that SRC-3 drives CRPC formation and offer preclinical proof of concept for a transcriptional coactivator as a therapeutic target to abrogate CRPC progression. Cancer Res; 73(13); 3997–4008. ©2013 AACR.